GLP-1 Receptor Agonists in Obesity Care: Clinical Promise, Nutritional Challenges, and Real-World Implications
Roshanak Soltani, Independent Researcher, Padova, Italy, MSc in Food and Health, University of Padua
GLP-1 receptor agonists have rapidly transformed obesity management, demonstrating substantial weight loss and cardiometabolic benefits. However, their growing use highlights challenges related to nutritional adequacy, long-term adherence, and real-world safety. This article examines clinical evidence, micronutrient considerations, and broader healthcare implications to support more integrated and sustainable obesity care strategies.
The GLP-1 Revolution in Obesity Management
The global burden of obesity has reached unprecedented levels, driving an urgent need for effective and scalable therapeutic strategies. In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a transformative pharmacological option, offering clinically meaningful weight reduction alongside cardiometabolic benefits. Agents such as semaglutide and tirzepatide have reshaped clinical expectations for obesity treatment, moving beyond the modest weight loss outcomes historically associated with lifestyle interventions alone.
However, as the adoption of GLP-1 therapies expands rapidly in both clinical practice and commercial markets, it has become increasingly important to evaluate their broader implications. Weight loss, while central, represents only one dimension of obesity care. Nutritional adequacy, long-term adherence, safety, and real-world effectiveness are critical factors in determining the sustainability and overall value of these therapies within healthcare systems.
Clinical Efficacy: What the Evidence Shows
Randomised controlled trials have consistently demonstrated the potent efficacy of GLP-1 receptor agonists in promoting weight loss. Large-scale studies such as the STEP and SURMOUNT trial programs reported average body weight reductions ranging from 15% to over 20% in individuals with obesity, substantially exceeding outcomes observed with previous pharmacotherapies.
Beyond weight loss, GLP-1 therapies have shown favorable effects on glycemic control, blood pressure, and lipid profiles, thereby reducing cardiometabolic risk. These benefits have positioned GLP-1 receptor agonists as cornerstone treatments not only for type 2 diabetes but also increasingly for obesity as a chronic disease.
Nevertheless, clinical trials are conducted under controlled conditions with intensive follow-up and structured support. Translating these outcomes into routine clinical practice presents distinct challenges, particularly when long-term treatment and sustained patient adherence are required.
Nutritional and Micronutrient Considerations
One of the less-discussed consequences of GLP-1–induced weight loss relates to nutritional adequacy. The pharmacological effects of GLP-1 receptor agonists—including delayed gastric emptying, reduced appetite, and early satiety—often lead to a substantial reduction in overall energy intake. While beneficial for weight loss, this reduction may inadvertently increase the risk of insufficient intake of essential nutrients.
Emerging evidence and clinical observations suggest potential risks for inadequate protein intake and deficiencies in key micronutrients such as iron, vitamin B12, calcium, and fat-soluble vitamins. Gastrointestinal side effects, including nausea and vomiting, may further exacerbate these risks, particularly during dose-escalation phases.
From a clinical and public health perspective, these findings underscore the importance of integrating nutritional monitoring and dietary counseling into GLP-1–based obesity treatment protocols. Addressing nutritional gaps early may help preserve lean body mass, support metabolic health, and enhance treatment sustainability.
Real-World Use: Adherence, Safety, and Long-Term Challenges
Real-world data increasingly highlight discrepancies between clinical trial outcomes and routine practice. Discontinuation rates for GLP-1 therapies remain notable, often driven by gastrointestinal side effects, cost, access issues, or unmet patient expectations regarding long-term weight maintenance.
Safety profiles observed in real-world settings are broadly consistent with trial data; however, long-term outcomes remain under active investigation. Questions persist regarding optimal treatment duration, weight regain following discontinuation, and strategies to support sustained behavioral change alongside pharmacotherapy.
These challenges highlight the need for real-world evidence studies and post-marketing surveillance to better inform clinical decision-making and healthcare policy.
Implications for Women of Reproductive Age
Women of reproductive age represent a particularly important population in the context of GLP-1 therapy. This group may be more vulnerable to micronutrient deficiencies due to higher baseline nutritional demands, as well as the potential impact of weight loss on menstrual function and fertility.
Despite the growing use of GLP-1 receptor agonists among women, data specific to reproductive health outcomes remain limited. This knowledge gap emphasises the need for targeted research and cautious clinical monitoring, particularly for women planning pregnancy or experiencing rapid weight loss.
Incorporating gender-specific considerations into obesity management strategies will be essential for delivering safe and equitable care.
Industry and Healthcare System Implications
From an industry perspective, the rise of GLP-1 therapies presents both opportunities and responsibilities. The expanding market for obesity pharmacotherapy has accelerated innovation across drug development, digital health, and personalised nutrition services.
Healthcare systems, however, must adapt to ensure that pharmacological interventions are embedded within multidisciplinary care models. Combining GLP-1 therapy with nutritional support, behavioral counseling, and long-term follow-up may enhance outcomes while mitigating unintended consequences such as nutritional deficiencies or treatment discontinuation.
For pharmaceutical companies and healthcare providers alike, the future of obesity care will depend on integrated, patient-centered approaches rather than standalone pharmacological solutions.
Conclusion:
Moving Beyond Weight Loss
GLP-1 receptor agonists have undeniably redefined the landscape of obesity treatment, offering unprecedented efficacy and renewed optimism for patients and clinicians. Yet their long-term success will depend on moving beyond weight loss as the sole outcome of interest.
By addressing nutritional adequacy, real-world adherence, and population-specific considerations, stakeholders can maximise the clinical and societal value of these therapies. An integrated approach—combining pharmacology, nutrition, and behavioral care represents the next evolution in sustainable obesity management.
References:
- Ryan DH & Kahan S. Guidelines for Obesity Management. NIH, 2018.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM, 2021.
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs withdrawal. JAMA, 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM, 2022.
- Davies MJ et al. Management of hyperglycemia and Type 2 Diabetes. NIH, 2022.
- Assessment reports on semaglutide and tirzepatide. EMA, 2022.
- Gleason PP et al. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. NIH, 2024.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024.
- Miller CK. Medical Nutrition Therapy: Still Relevant in the Era of Pharmacotherapy for Obesity Care. Journal of the Academy of Nutrition and Dietetics, 2025.
- Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. NIH, 2026.
Roshanak Soltani is a nutritionist with academic training in Food and Health Sciences. She holds a Master of Science degree from the University Of Padua, Italy. Her work focuses on the clinical and metabolic effects of dietary and pharmacological interventions in obesity management, with particular emphasis on GLP-1–based therapies, micronutrient status, and evidence-informed strategies to support long-term metabolic health.
